Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618943 | 0.86 | TP53 (0.30) | TP53TDP1 | |
| SCHEMBL189595 | 0.86 | TP53 (0.30) | TP53TDP1 | |
| SCHEMBL5229008 | 0.84 | — | — | |
| SCHEMBL29279392 | 0.84 | SLC22A8 (0.30) | — | |
| SCHEMBL4359969 | 0.82 | — | — | |
| SCHEMBL3819396 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL11018648 | 0.80 | — | — | |
| SCHEMBL10850669 | 0.78 | ALDH1A1 (0.39) | TDP1ALDH1A1 | |
| SCHEMBL11661670 | 0.78 | ALDH1A1 (0.38) | TP53TDP1ALDH1A1 | |
| SCHEMBL31391761 | 0.78 | ALDH1A1 (0.38) | TP53TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9360567-B2 | Scintillating organic materials and methods for detecting neutron and gamma radiation | NANOPTICS, INCORPORATED (US) | 2016-06-07 | — | — | US | claimed |
| US-20140224993-A1 | SCINTILLATING ORGANIC MATERIALS AND METHODS FOR DETECTING NEUTRON AND GAMMA RADIATION | NANOPTICS, INCORPORATED (US) | 2014-08-14 | — | — | US | claimed |
| US-9759821-B2 | Scintillating organic materials and methods for detecting neutron and gamma radiation | NANOPTICS, INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| US-9360567-B2 | Scintillating organic materials and methods for detecting neutron and gamma radiation | NANOPTICS, INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160154122-A1 | Scintillating Organic Materials and Methods For Detecting Neutron and Gamma Radiation | NANOPTICS, INCORPORATED | 2016-06-02 | — | — | US | disclosed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | disclosed |
| US-7671094-B2 | Bupropion hydrobromide and therapeutic applications | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-03-02 | — | — | US | disclosed |
| US-7662407-B2 | hydrobromide salt; for treatment of depression, nicotine addiction and obesity | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-02-16 | — | — | US | disclosed |
| US-7649019-B2 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-01-19 | — | — | US | disclosed |
| US-7645901-B2 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-01-12 | — | — | US | disclosed |
| US-7645802-B2 | Controlled release, once daily formulation; reducing seizure side effects; antidepressant | BIOVAIL LABORATORIES INTERNATIONAL SRL. (BB) | 2010-01-12 | — | — | US | disclosed |
| US-20080057120-A1 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-03-06 | — | — | US | disclosed |
| US-20080051606-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-28 | — | — | US | disclosed |
| US-20080039441-A1 | Storage stability; combination forms with antidepressants, antiinflammatories, serotonin reuptake inhibitors, antiemetics, appetite modulators, antivirals, vasodilators and/or pain relievers | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-14 | — | — | US | disclosed |
| US-20080038348-A1 | Dosage form releases bupropion hydrobromide by dispensing it from a core via at least one passageway in a membrane by pressure created in the core by osmosis and/or by the expansion of a swellable material which forces the bupropion hydrobromide to be dispensed from core | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-14 | — | — | US | disclosed |
| US-20080038345-A1 | Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form | BIOAVAIL LABORATORIES (BB) | 2008-02-14 | — | — | US | disclosed |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES (BB) | 2008-02-07 | — | — | US | disclosed |
| US-20080033043-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-07 | — | — | US | disclosed |
| US-20070293584-A1 | hydrobromide salt; for treatment of depression, nicotine addiction and obesity | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-12-20 | — | — | US | disclosed |
| US-20070281012-A1 | MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057120-A1 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | SLC6A2, BDNF, SLC6A11 | TP53 4754/4885TDP1 2444/4885ALDH1A1 3143/4885 |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | TP53 4525/4885TDP1 2850/4885ALDH1A1 3922/4885 |
| US-20070281012-A1 | MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT | SLC6A2, SLC6A3, SLC6A11 | TP53 4820/4885TDP1 570/4885ALDH1A1 2619/4885 |
| US-20080033043-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | TP53 4525/4885TDP1 2850/4885ALDH1A1 3922/4885 |
| US-20080051606-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | TP53 4525/4885TDP1 2850/4885ALDH1A1 3922/4885 |
| US-20080039441-A1 | Storage stability; combination forms with antidepressants, antiinflammatories, serotonin reuptake inhibitors, antiemetics, appetite modulators, antivirals, vasodilators and/or pain relievers | SLC6A4, HTR5A, SLC6A2 | TP53 4740/4885TDP1 1493/4885ALDH1A1 3089/4885 |
| US-20070293584-A1 | hydrobromide salt; for treatment of depression, nicotine addiction and obesity | SLC6A3, SLC6A2, SLC6A4 | TP53 4780/4885TDP1 1656/4885ALDH1A1 976/4885 |
| US-20080038345-A1 | Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form | SLC6A2, SLC6A4, SLC6A3 | TP53 4164/4885TDP1 2040/4885ALDH1A1 1530/4885 |
| US-20080038348-A1 | Dosage form releases bupropion hydrobromide by dispensing it from a core via at least one passageway in a membrane by pressure created in the core by osmosis and/or by the expansion of a swellable material which forces the bupropion hydrobromide to be dispensed from core | SLC6A11, SLC6A1, SLC6A5 | TP53 4430/4885TDP1 1139/4885ALDH1A1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.